Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7131450 | 0.85 | MAPT (0.55) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL7440297 | 0.82 | KMT2A (0.54) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL23014282 | 0.82 | ALDH1A1 (0.73) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL28484131 | 0.82 | ALDH1A1 (0.73) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL9837130 | 0.82 | PTPN1 (0.52) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL11216066 | 0.81 | MEN1 (0.62) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL3672269 | 0.81 | NPC1 (0.60) | MAPTALDH1A1LMNANPC1RAB9A | |
| Methane SCHEMBL9835792 | 0.80 | NPC1 (0.50) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL14830961 | 0.80 | ERCC5 (0.58) | MAPTALDH1A1LMNANPC1RAB9A | |
| SCHEMBL10187752 | 0.80 | GSK3B (0.55) | MAPTALDH1A1NPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028052-B2 | Compounds useful as modulators of TRPM8 | FIRMENICH INCORPORATED (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3461816-B1 | FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10421727-B2 | Compounds useful as modulators of TRPM8 | FIRMENICH INCORPORATED (US) | 2019-09-24 | — | — | US | disclosed |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) | 2019-07-23 | — | — | US | disclosed |
| EP-3461816-A1 | FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| WO-2018165520-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VPS-3, INC. (US) | 2018-09-13 | — | — | WO | disclosed |
| US-20170369447-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2017-12-28 | — | — | US | disclosed |
| US-9840471-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150376136-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. | 2015-12-31 | — | — | US | disclosed |
| EP-2958897-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014130582-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421727-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM7, TRPA1 | MAPT 1245/4885ALDH1A1 1692/4885LMNA 4037/4885 |
| US-20150376136-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM7, TRPA1 | MAPT 1245/4885ALDH1A1 1692/4885LMNA 4037/4885 |
| US-20180256572-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | MAPT 456/4885ALDH1A1 244/4885LMNA 4039/4885 |
| US-20170369447-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM7, TRPA1 | MAPT 1245/4885ALDH1A1 1692/4885LMNA 4037/4885 |
| US-11028052-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM7, TRPA1 | MAPT 1245/4885ALDH1A1 1692/4885LMNA 4037/4885 |
| US-10357493-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | MAPT 456/4885ALDH1A1 244/4885LMNA 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.